Enalapril Bp en es it fr

Categoria

Enalapril Bp Nombres de marca, Enalapril Bp Analogos

Enalapril Bp Marca los nombres de mezcla

  • Vaseretic (Enalapril Maleate + Hydrochlorothiazide)
  • Enalapril Bp Formula quimica

    C20H28N2O5

    Enalapril Bp RX enlace

    http://www.rxlist.com/cgi/generic/enalap.htm

    Enalapril Bp FDA hoja

    Enalapril_Bp FDA

    Enalapril Bp MSDS (hoja de seguridad de materiales)

    Enalapril Bp Sintesis de referencia

    A. Patchett et al., Nature 288, 280 (1980)

    Enalapril Bp Peso molecular

    376.447 g/mol

    Enalapril Bp Punto de fusion

    143-144.5oC

    Enalapril Bp H2O Solubilidad

    0.025g/mL

    Enalapril Bp Estado

    Solid

    Enalapril Bp LogP

    2.271

    Enalapril Bp Formas de dosificacion

    Tableta, inyección IV

    Enalapril Bp Indicacion

    Para el tratamiento de la hipertensión y la insuficiencia cardiaca. Se puede utilizar solo o en combinación con diuréticos tiazídicos.

    Enalapril Bp Farmacologia

    Enalapril, una enzima convertidora de la angiotensina (ECA), es un profármaco que, cuando se hidroliza por estarases a su enalaprilato activo, se utiliza para tratar la hipertensión y la insuficiencia cardiaca, para reducir la proteinuria y la enfermedad renal en pacientes con nefropatías, y para evitar accidente cerebrovascular, infarto de miocardio y muerte cardíaca en pacientes de alto riesgo. Enalapril y enalaprilato inhibir la enzima convertidora de angiotensina (ACE) en seres humanos y animales. La ECA es una peptidil dipeptidasa que cataliza la conversión de angiotensina I en la sustancia vasoconstrictora de la angiotensina II. La angiotensina II también estimula la aldosterona la secreción de la corteza suprarrenal.

    Enalapril Bp Absorcion

    60%

    Enalapril Bp Toxicidad

    Hipotensión

    Enalapril Bp Informacion de Pacientes

    Angioedema: Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.

    Hypotension: Patients should be cautioned to report lightheadedness, especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician.

    All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

    Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician. Neutropenia: Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia.

    Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACEinhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

    NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

    Enalapril Bp Organismos afectados

    Humanos y otros mamíferos